Distributions of the potential and electric field of an electrode elliptic array used in tumor electrotherapy: Analytical and numerical solutions

To estimate the potential and electric field generated by any electrode array is very useful in effective tumor destruction. At present, an electrode array that takes into account the ellipsoidal geometry of the solid tumors has not been proposed. We present both analytical and numerical solutions for the potential and electric field in a solid tumor established by an electrode array with elliptic shape which may be used in vitro, in vivo and in clinical studies for cancer treatment with electrotherapy. These analytical and numerical solutions are obtained using multipole expansion and the finite difference method. Distributions of potential and electric field magnitudes are computed in function of the eccentricity of an elliptical array and compared with those obtained with a circular array of electrode. Maximum difference and Root Means Square Error are used to compare the distributions of the potential and electric field in leading-order and first-order correction and between the analytical and numerical solutions. The results show a good agreement between these distributions in both orders and the analytical and numerical solutions. It was concluded that the mathematical approach presented in this study is a tool for a rapid design of electrode elliptical arrays in order to induce the maximum destruction of the tumor. Moreover, it is shown that, for all values of eccentricity, there is a good correspondence between the distributions of the potential and the electric field for leading-order and first-order correction and for both the analytical and numerical solutions.     

Novel copolymers of styrene. 1. Alkyl ring-substituted 2-cyano-3-phenyl 2-propenamides

Novel electrophilic trisubstituted ethylene monomers, alkyl ring-substituted 2-cyano-3-phenyl-2-propenamides, RC₆H₄CH=C(CN)CONH₂ (where R is 2-methyl, 3-methyl, 4-methyl, 4-ethyl, 4-i-propyl, 4-i-butyl, and 4-t-butyl), were synthesized by potassium hydroxide catalyzed Knoevenagel condensation of ring-substituted benzaldehydes and cyanoacetamide, and characterized by CHN elemental analysis, IR, ¹H- and ¹³C-NMR. Novel copolymers of the ethylenes and styrene were prepared at equimolar monomer feed composition by solution copolymerization in the presence of a radical initiator, AIBN at 70 °C. The composition of the copolymers was calculated from nitrogen analysis, and the structures were analyzed by IR, ¹H- and ¹³C-NMR, GPC, DSC, and TGA. High T _g of the copolymers in comparison with that of polystyrene indicates a substantial decrease in chain mobility of the copolymer due to the high dipolar character of the trisubstituted ethylene monomer unit. Decomposition of the copolymers in nitrogen occurred in two steps, first in the 200–500 °C range with residue (5–7 wt%), which then decomposed in the 500–800 °C range.     

EFFECT OF NUCLEOTIDE SEQUENCE ON THE BINDING OF (–)–ANTI–DIBENZO– [a,l]PYRENE–11,12–DIOL 13,14–EPOXIDE TO SHORT OLIGODEOXYRIBONUCLEOTIDES

Abstract

Seven selfcomplementary decamer oligodeoxyribonucleotides were reacted with (–)–anti–(11R,12S)–dihydrodiol (13S,14R)–epoxide of dibenzo[a,l]pyrene (DB[a,l]PDE). The oligodeoxyribonucleotides were postlabeled with ³³P–ATP, digested to mononucleotides and the amount of adducts formed was determined by HPLC. We found that the nucleotide sequence affects the binding of DB[a,l]PDE to DNA. DB[a,l]PDE binds better to GC rich oligodeoxyribonucleotides than to AT rich oligodeoxyribonucleotides. The CGC sequence binds more DB[a,l]PDE than GGC, TGC, GAT or AGC sequences. The reactions were carried out on ice or at 37°C. There was no evidence of temperature effects on the amount of DB[a,l]PDE binding.     

Magnetic Nanosystem for Cancer Therapy Using Oncocalyxone A,an Antitomour Secondary Metabolite Isolated from a Brazilian Plant

This paper describes the investigation and development of a novel magnetic drug delivery nanosystem (labeled as MO-20) for cancer therapy. The drug employed was oncocalyxone A (onco A), which was isolated from Auxemma oncocalyx, an endemic Brazilian plant. It has a series of pharmacological properties: antioxidant, cytotoxic, analgesic, anti-inflammatory, antitumor and antiplatelet. Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties. The components of MO-20 were characterized by XRD, FTIR, TGA, TEM and Magnetization curves. The MO-20 presented a size of about 30 nm and globular morphology. In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport. The results found in this work showed the potential of onco A for future applications of the MO-20 as a new magnetic drug release nanosystem for cancer treatment.     

Brain Recovery after a Plane Crash: Treatment with Growth Hormone (GH) and Neurorehabilitation: A Case Report

The aim of this study is to describe the results obtained after growth hormone (GH) treatment and neurorehabilitation in a young man that suffered a very grave traumatic brain injury (TBI) after a plane crash. Methods: Fifteen months after the accident, the patient was treated with GH, 1 mg/day, at three-month intervals, followed by one-month resting, together with daily neurorehabilitation. Blood analysis at admission showed that no pituitary deficits existed. At admission, the patient presented: spastic tetraplegia, dysarthria, dysphagia, very severe cognitive deficits and joint deformities. Computerized tomography scanners (CT-Scans) revealed the practical loss of the right brain hemisphere and important injuries in the left one. Clinical and blood analysis assessments were performed every three months for three years. Feet surgery was needed because of irreducible equinovarus. Results: Clinical and kinesitherapy assessments revealed a prompt improvement in cognitive functions, dysarthria and dysphagia disappeared and three years later the patient was able to live a practically normal life, walking alone and coming back to his studies. No adverse effects were observed during and after GH administration. Conclusions: These results, together with previous results from our group, indicate that GH treatment is safe and effective for helping neurorehabilitation in TBI patients, once the acute phase is resolved, regardless of whether or not they have GH-deficiency (GHD).